Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.
from The Medical News http://ift.tt/1DTxfL5
from The Medical News http://ift.tt/1DTxfL5
No comments:
Post a Comment